Pharmaceuticals

Global RNA Targeting Small Molecule Drug Discovery Market Trends and Growth Analysis 2025–2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The RNA Targeting Small Molecule Drug Discovery Market Over The Five-Year Period 2025–2029?

The RNA targeting small molecule drug discovery market has shown considerable expansion in recent years. It is anticipated to increase from $1.76 billion in 2024 to $2.13 billion in 2025, reflecting a compound annual growth rate (CAGR) of 20.8%. This historical growth can be attributed to an increased understanding of disease genetics, genomic and proteomic discoveries, drug resistance challenges, investment in biotechnology and pharmaceutical research, and the rise of RNA therapeutics.

The RNA targeting small molecule drug discovery market is set to experience significant expansion in the coming years. It is projected to reach $4.85 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 22.9%. This anticipated growth during the forecast period can be attributed to the increasing scope of RNA epigenetics research, developments in RNA-seq and functional genomics, the integration of artificial intelligence (AI), patient-centric approaches, and exosome-mediated drug delivery. Prominent trends for the forecast period include the emergence of RNA editing technologies, continued progress in CRISPR technology, broader technological innovations, advancements in RNA biology, and the application of RNA targeting in neurodegenerative diseases.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Factors And Drivers Are Influencing The RNA Targeting Small Molecule Drug Discovery Market In 2025?

The anticipated expansion of the RNA-targeted small-molecule drug discovery market is driven by the rising occurrence of cancer, genetic conditions, and viral ailments. Cancer encompasses a range of illnesses marked by unchecked cellular proliferation within the body. Viral infections are defined as ailments initiated by viruses, which are microscopic infectious entities capable of replication solely within the host cells of living organisms. RNA targeting-based drug discovery offers therapeutic approaches for cancer, genetic disorders, and viral infections, given that these conditions are associated with genes and dysfunctional genetic material, amenable to treatment through pharmaceuticals developed via RNA targeting techniques. For example, a report released in February 2024 by the World Health Organization (WHO), an intergovernmental body based in Switzerland, reported approximately 20 million new cancer diagnoses and 9.7 million global fatalities in 2022. Lung cancer emerged as the most prevalent, accounting for 2.5 million new instances (12.4%), succeeded by female breast cancer with 2.3 million cases (11.6%), colorectal cancer at 1.9 million cases (9.6%), prostate cancer with 1.5 million cases (7.3%), and stomach cancer totaling 970,000 cases (4.9%). Projections indicate that by 2050, the incidence of new cancer cases will surge by 77%, surpassing 35 million each year. Consequently, the expanding burden of cancer, genetic disorders, and viral infections is a key factor propelling the expansion of the RNA-targeted small-molecule drug discovery market.

Which Key Segments Fueling The RNA Targeting Small Molecule Drug Discovery Market?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies

3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

How Are Emerging Market Trends Shaping The RNA Targeting Small Molecule Drug Discovery Industry Landscape?

The integration of Artificial intelligence (AI) into drug discovery represents a key trend gaining significant popularity in the small-molecule drug discovery market. Leading companies within the small molecule drug discovery market are leveraging AI technology to expedite drug discovery procedures, thereby maintaining their competitive standing. For instance, in May 2023, Google Cloud, the cloud computing suite offered by Google, a US-based technology company, introduced the Target and Lead Identification Suite and the Multiomics Suite to facilitate the drug discovery process. The Multiomics Suite helps to accelerate the identification and analysis of genetic data, assisting businesses in the design of precision medicines. Additionally, the Target and Lead Identification Suite aids researchers in gaining a deeper understanding of the role of amino acids and in predicting the structure of proteins.

Who Are The Key Multinational Companies Dominating The RNA Targeting Small Molecule Drug Discovery Market?

Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Regional Markets Are Contributing Most To The RNA Targeting Small Molecule Drug Discovery Industry Expansion?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The RNA Targeting Small Molecule Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Browse Through More Reports Similar to the Global RNA Targeting Small Molecule Drug Discovery Market 2025, By The Business Research Company

Drug Discovery Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-global-market-report

Drug Discovery Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report

Drug Discovery Informatics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/drug-discovery-informatics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795